predicting outcomes of advanced non-small cell lung cancer patients treated with pd-1/pdl
Published 2 years ago • 53 plays • Length 4:13Download video MP4
Download video MP3
Similar videos
-
5:40
long term overall survival with advanced non-small cell lung cancer treated with pembrolizumab
-
7:20
new phase 3 data on pd-l1 vs. chemotherapy for first-line nsclc
-
2:54
pioneer: understanding pd-l1 resistances in non-small cell lung cancer
-
4:55
long-term outcomes with pd-1 monotherapy in nsclc
-
10:32
upfront pd-1 inhibitor treatment for nsclc: a new paradigm
-
5:11
predictors of immunotherapy response in lung cancer - biomarkers, mutational load and tumor biology
-
49:54
practical principles of biomarker testing in advanced non-small cell lung cancer
-
5:16
pembrolizumab found to be safe with durable responses in advanced, non-small cell lung cancer
-
1:24
transforming outcomes in advanced lung cancer: immunotherapy in unselected patients
-
4:52
targeting the immune system in non-small cell lung cancer
-
3:48
final data of eftilagimod alpha and pembro in pd-1/pd-l1 inhibitors resistant 2l metastatic nsclc
-
8:22
pd-l1 expression predicts which solid tumor patients will respond to pd-1/pd-l1 treatment
-
3:02
survival-predicting algorithm passes first big test in patients with lung cancer
-
1:07
integration of radiology, pathology, & genomics for prediction of response to anti-pd-1 in nsclc
-
5:44
reliability of pd-l1 testing in nsclc
-
1:57
targeting pd-1 and pd-l1 for lung cancer therapy
-
11:18
key takeaways from esmo: updates on small-cell lung cancer
-
2:19
combining ctla-4 agents with pd-1/pd-l1 agents in lung cancer